IceCure Medical (ICCM) Stock Price, News & Analysis

Company Overview

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Key Stats

• Today's Range: $0.78 to $0.87
• 50-Day Range: $0.79 to $1.15
• 52-Week Range: $0.48 to $1.66
• Volume: 514,583 shs
• Average Volume: 2.78 million shs
• Market Capitalization: $49.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.64
• Consensus Rating: Buy

IceCure Medical Stock Analysis - MarketRank™

IceCure Medical scored higher than 46% of companies evaluated by MarketBeat, and ranked 641st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

IceCure Medical has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

IceCure Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IceCure Medical are expected to grow in the coming year, from ($0.28) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IceCure Medical is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IceCure Medical is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IceCure Medical has a P/B Ratio of 7.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.07% of the float of IceCure Medical has been sold short.

Short Interest Ratio / Days to Cover

IceCure Medical has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IceCure Medical has recently increased by 393.86%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IceCure Medical does not currently pay a dividend.

Dividend Growth

IceCure Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.07% of the float of IceCure Medical has been sold short.

Short Interest Ratio / Days to Cover

IceCure Medical has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IceCure Medical has recently increased by 393.86%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.44

News Sentiment

IceCure Medical has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for IceCure Medical this week, compared to 2 articles on an average week.

Search Interest

18 people have searched for ICCM on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added IceCure Medical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IceCure Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.44% of the stock of IceCure Medical is held by insiders.

Percentage Held by Institutions

Only 0.62% of the stock of IceCure Medical is held by institutions.

ICCM Stock Analysis - Frequently Asked Questions

How have ICCM shares performed this year?

IceCure Medical's stock was trading at $1.10 at the start of the year. Since then, ICCM stock has decreased by 23.5% and is now trading at $0.8416.

How were IceCure Medical's earnings last quarter?

IceCure Medical Ltd. (NASDAQ:ICCM) posted its quarterly earnings data on Wednesday, August, 13th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.12. The company had revenue of $0.66 million for the quarter, compared to the consensus estimate of $0.90 million. IceCure Medical had a negative net margin of 317.62% and a negative trailing twelve-month return on equity of 115.66%.
Read the conference call transcript.

How do I buy shares of IceCure Medical?

Shares of ICCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IceCure Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IceCure Medical investors own include Medical Properties Trust (MPW), Realty Income (O), Oxford Square Capital (OXSQ), PayPal (PYPL), A.P. Moller-Maersk (AMKBY), Annaly Capital Management (NLY) and Oxford Lane Capital (OXLC).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:ICCM
• CIK: 1584371
• Web: www.icecure-medical.com
• Phone: 972-4623-0333
• Fax: 972-4623-0222
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for IceCure Medical: $2.64
• High Price Target: $2.77
• Low Price Target: $2.50
• Potential Upside/Downside: +213.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.32 million
• Net Margins: -317.62%
• Pretax Margin: -465.45%
• Return on Equity: -115.66%
• Return on Assets: -68.17%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 1.89
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: $3.29 million
• Price / Sales: 15.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.12 per share
• Price / Book: 7.01

Miscellaneous

• Outstanding Shares: 58,700,000
• Free Float: 57,265,000
• Market Cap: $49.40 million
• Optionable: Not Optionable
• Beta: 0.32